New Venturetec
New Venturetec (NEV) erreicht heute 27. März erstmals wieder seit Jahren die Kursregion 32/34 CHF. Der Buchwert wird erstmals wieder in etwa erreicht. Kurs ist nicht sehr volatil, steigt einfach langsam an. Halten und dabeibleiben? Interessanter Venture Capitalist für risikobereite Sponsoren auch auf diesem Niveau?
Hält sich erstaunlich robust? staun?
Nachfassen hat sich gelohnt
Hatte ja beim Börsengang von Basilea mal in der Gegend 22/24 zum Risiko-Nachkauf pokermässig geraten mit Ziel CHF 40 hopp, das ging dann bis CHF 27 und zu Tale adieu. Das ist auch schon ein/zwo Jährchen her, diese nachgebunkerte Fraktion ist jedenfalls über Einstand. Halt nur für echte Venture-Capitalisten im brasilianischen Dschungel, so hat das Herr Friedli bildhaft beschrieben.
Hinvweis
Hinweis 30 März, der Chart hat aus einem langsamen Aufwärtstrend abgehoben, notiert heute 35 CHF. Kann den Wert nicht fundamental einschätzen, läuft jetzt zusammen mit dem berechneten Buchwert, ev. Fantasie für neuen Börsengang. Pokermässig drinbleiben. Wert zeigt wenig Volatilität, ist kursmässig robust, vermutlich nur wenige echte langfrist Venture-Capitalisten und kaum Zocker investiert?
Halbjahresbericht
Kopiere hier ab pdf mit Textauswahlwerkzeug den Halbjahresbericht von New Venturetec. Man beachte die Berechnung des Inneren Wertes der Beteiligung. Der Kurs wird derzeit mit einem Aufschlag gehandelt, was in Anbetracht der Perspektiven gerechtfertigt sein mag. Ziel CHF 40+ bleibt stehen, die Marke von 30 wurde genommen und stabil verteidigt. Kurs zeigt kaum Schwäche. Ist ab CHF 24 in kleiner Portion nachgekauft und bleibt liegen.
NEW VENTURETEC
New Venturetec phone +41 44 283 29 00
Freigutstrasse 5 fax +41 44 283 29 01
8002 Zurich e-mail: peter.friedli@friedlicorp.ch
Switzerland www.newventuretec.com
Press Release
For further information:
Peter Friedli
Freigutstrasse 5
8002 Zürich
Tel: 044/283 29 00
Email: peter.friedli@friedlicorp.ch
New Venturetec with good results
NAV Increase of 15.2% - profit increase of 113.8% - share price increase of 50.0%
Results for the six months period ending March 31, 2006
Zürich, May 3, 2006. New Venturetec closed the first six months for fiscal year 05/06, ended March 31,
2006, with a profit of USD 16'636'644.00, against USD 4'432'803.00 in the same period of the fiscal year
04/05 (not comparable figure due to change in accounting policy, comparable figure USD 7'780'967.00).
The net asset value per share increased from USD 21.95 to USD 25.28 which equals 15.2% during the
reporting six month period; in CHF respectively from 28.26 to 32.97 or 16.6%. The share price in the
same period increased from CHF 24.00 to CHF 36.00, or 50.0%. The share price on March 31, 2006
traded at a 9.2% premium to the net asset value.
The net gain on investments of the reporting period is USD 20'108'493.00 compared to USD
13'437'408.00 in the same period 2005. The main reasons for the increase are Basilea Pharmaceutica
with USD 12'131'890.00 or 27.9% and Osiris Therapeutics with USD 7'105'000.00 or 20.3%.
The operational progress of the portfolio companies is evident. As of March 31, 2006, New Venturetec
had ten investments with four investments valued higher than the investment costs, five at cost and one
below investment costs. The total amount of investment is USD 124'821'476.00 which results in an
unrealized gain of USD 60'141'194.00 or 48.2% compared to the net asset value of USD
184'962'670.00. There was no management fee or board remuneration paid in the reporting period but
rather accrued.
The semi-annual report, including financial statements for the reporting period can be downloaded from
www.newventuretec.com.
New Venturetec is a publicly traded Swiss investment company (SWX: NEV) which invests directly in
Venture Capital Companies in the USA.
The Semi-Annual Conference takes place May 9 in the CS Forum St. Peter, St. Peterstrasse 19, 8001
Zurich from 11.45 until 13.30. The following companies will present: Iperia, WStore and mPortal.
IPO Osiris Therapeutics
..demnächst IPO Osiris Therapeutics, spült wohl zukünftig den Aktienkurs von NEV nach oben
https://www.osiristx.com/
https://www.osiristx.com/news2.php?id=38
IPO Road Show am 19. Juli mit Osiris Mgmgt und P. Friedli
Osiris Therapeutics will hold an IPO Road Show Presentation on Wednesday, July 19, 2006, from 12.00 to 13.30 at the Park Hyatt, Beethovenstrasse 21, 8022 Zurich.
If you wish to participate on this presentation please kindly replay to this email.
If you wish a one-on-one meeting with the management of Osiris please contact us.
Sincerely
Peter Friedli
************************
Peter Friedli
Friedli Corporate Finance
Freigutstrasse 5
8002 Zürich
Switzerland
Tel: +41 44 283 2900
Fax: +41 44 283 2901
Email: peter.friedli@friedlicorp.ch
Internet: www.newventuretec.com,
www.inventureltd.com
Osiris Therapeutics/ OSIR, gelistet an der Nasdaq....
...sofern alles gut läuft in den ersten 10 Tagen im August 06!
Muss sagen, Osiris Chairman Peter Friedli macht da ganze Arbeit, direkt an die Nasdaq - das tönt cool
AP
IPO Spotlight: Osiris Therapeutics
Friday July 28, 4:11 pm ET
By Wallace Witkowski, AP Business Writer
Osiris Therapeutics Plans Public Debut Into Volatile Stem Cell Biotech Market
NEW YORK (AP) -- Amid the recent controversy surrounding stem cell research, Osiris Therapeutics Inc. plans to join the small cadre of publicly traded biotech companies developing treatments using the technology, setting itself apart as the only company with a stem cell treatment on the U.S. market.
However, the Baltimore-based biotech company enters a challenging market for stem cell companies, in which stock prices tend to get worse before they get better.
Last week, Osiris said in a filing with the Securities and Exchange Commission it will sell 3.5 million shares at $11 to $13 apiece in its initial public offering, slated for July 31. An additional 525,000 shares will be made available to underwriters for overallotments. Jefferies & Co. is the lead bookrunning manager and Lazard Capital Markets is acting as co-lead manager.
In the company\'s original May registration statement, Osiris filed to sell up to $80 million of its shares. Under the amended registration, the company would only sell $38.5 million to $45.5 million worth of shares.
So far this year, eight biotech companies have launched IPOs, and seven others filed proposals.
Rich Peterson, a research analyst with Thomson Financial, said biotech stocks that have debuted this year are off an average of 9 percent, while stocks that debuted last year are off an average of 3 percent from their initial price.
"In general biotech IPOs are hard pressed," said Peterson in an interview. "It\'s the nature of business: they generally don\'t have established products, and are hoping to hit it big."
On the whole, Peterson said the year has been pretty flat for IPOs, with notable successes like J. Crew and Chipolte balanced by disappointments like Vonage.
In its latest filing, Osiris sets itself apart from competitors by saying it sells the only commercially available product in the United States containing viable stem cells. The product, Osteocel, is used to regenerate bone. Launched in July 2005, Osiris booked Osteocel sales of $957,000 in 2005, and $1.1 million in the quarter ended March 31. Osiris uses stem cells harvested from adult bone marrow.
The business plans to develop products that prevent the rejection of bone marrow transplants in cancer patients, heal heart tissue after a heart attack, and regenerate tissue following knee injuries to prevent arthritis. The company has a strategic alliance with medical device maker Boston Scientific Corp. for the heart application.
Founded in 1992, the company said in its filing it has spent $147.7 million to date and expects losses to continue "for at least the next several years." In 2005, the company posted a loss of $20 million, and recorded a loss of $5.1 million in the quarter ended March 31.
Currently, Osiris Chairman Peter Friedli owns 54 percent of shares and Swiss investment firm Venturetec Inc., where Friedli acts as president, owns 13 percent. After the offering, Friedli will own 48 percent of the company, and Venturetec will hold 12 percent of the roughly 27 million outstanding shares.
Osiris plans to use proceeds for research and development, general corporate purposes, and possibly to prepay principal and interest on a promissory note.
The company has three products in development: Prochymal for bone marrow transplant use, Provacel for repairing heart tissue, and Chondrogen for regenerating knee cartilage.
Prochymal is the farthest along, and is about to enter late-stage clinical trials. Prochymal is designated an orphan drug with a fast-track review by the Food and Drug Administration, meaning that the company can submit data as it becomes available -- rather than having to wait to submit it all at once -- and that the drug will receive seven years of marketing exclusivity if approved.
In April, the company completed enrollment for an early-to-mid-stage clinical trial for Chondrogen, and an early-stage clinical trial for Provacel.
Compared with those of their larger biotech counterparts, stock prices of smaller stem cell technology companies have steadily drifted toward 52-week lows in the past year. Publicly traded companies include StemCells Inc., Aastrom Biosciences Inc., ViaCell Inc. and Geron Corp., the only publicly traded company to use embryonic stem cells in research.
In comparison, the American Stock Exchange\'s Biotechnology Index, which follows 20 biotech companies, is up about 4 percent from a year ago.
Stem cells extracted from embryos are controversial because the embryos are destroyed in the process. Last week, President Bush used the first veto of his presidency to block a bill to allow more federal funding for embryonic stem cell research. Congress did not produce enough votes to overturn the veto.
Osiris plans to trade on the Nasdaq under the ticker symbol "OSIR."
Osiris Announces Pricing of Its Initial Public Offering
ORISIS - heute 1. Handelstag an der NASDAQ, ab 17:00 Uhr
Osiris Announces Pricing of Its Initial Public Offering
August 4, 2006 Baltimore, Maryland - Osiris Therapeutics, Inc. announced today the pricing of its initial public offering of 3,500,000 shares of its common stock at a price of $11.00 per share. All of the shares are being sold by the Company. Up to an additional 525,000 shares have been made available to the underwriters to cover over-allotments, if any. Osiris€™ common stock is expected to begin trading on The NASDAQ Global Market on Friday August 4, 2006 under the symbol "OSIR."
The shares are being offered by an underwriting syndicate led by Jefferies and Company acting as the bookrunning manager with Lazard Capital Markets and Leerink Swann and Company acting as the Co-Lead and Co-Manager, respectively. This offering will be made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Jefferies and Company, 520 Madison Avenue, 12th Floor, New York, NY 10022 or by fax request at (212) 284-2208.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 3, 2006. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction or state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or state.
About Osiris Therapeutics
Osiris Therapeutics, Inc. (NASDAQ:OSIR) is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and ardiovascular areas. Osiris currently markets and sells Osteocel® for regenerating bone in orthopedic indications. Prochymal„ is entering Phase III clinical trials and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. The Company€™s pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen„ for regenerating cartilage in the knee, and Provacel„, for repairing heart tissue following a heart attack. Osiris is a fully integrated company, having developed stem cell capabilities in research and development, manufacturing, marketing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company€™s technology in the United States and a number of foreign countries including 45 U.S. and 153 foreign patents owned or licensed.
For additional information, please contact Lisa Rodemann at 410.522.5005, extension 610.
danke für Hinweis
Danke für den Hinweis, Hans. OSIR ist auf Swissquote bereits gelistet. Wollen dann sehen mit welchen Kursen ab 17:00. New Venturtec notiert nach Konsolidierung auf 28/29 CHF. Bleibt auf der Waschliste, derzeit nicht investiert. Die Optionstermine und die Kriegspeitscherei werden die Märkte schon noch etwas durchschütteln.
Kurs ist 11 auf 20 gestellt, sehe noch keine gehandelten Volumen 500 auf 35000 gestellt. Kurs hielt sich in engen Bandbreiten bei winzigen Umsätzen um die 11$. Nicht grad ein spektakulärer Börsengang. Immerhin waren Papiere nahe am Emissionspreis handelbar für Osiris-Fans. Halte mich einstweilen zurück, da mir zuviel in Buchverlusten lagert, was ums Verrecken nicht mehr hochkommen darf.
stark
Die meisten User im Risikobereicht haben nach wie vor das Visier falsch eingestellt. New Venturetec konsolidierte nach Kursen weit über CHF 30 (Verkauf) in die Gegend der tiefen 20er. Ganz überraschend erfolgte heute ein Schub wieder auf über 30. Die Begründung liegt in der Kursfantasie von Osiris (Emission 11$ heute 18$) mit interessanten klinischen Resultaten auch von Erfolgsmeldungen von Basilea. Kurse bewegen sich im Fantasiebereich auf der Basis klinischer Erfolge. Bin nicht investiert (Oktober-Gefahr) beobachte jedoch die Szene.
unqualifiziert
Das ist wohl wieder ziemlicher Humbug Globalist. NEV berechnet periodisch den inneren Wert. Er zieht auch nicht raketenmässig mit irgendwelchen kurstreibenden Aktivitäten mit. Die Bewertungen der x-Beteiligungen sind eher konservativ angesiedelt. Also halte Dich besser raus oder recherchiere seriös und fundiert auf dieser Plattform.
Venture Capital ist nun mal Risiko und riskant, deshalb besser nichts schreiben, wenn Du eine negative Meinung vertrittst. Es zwingt Dich ja
niemand ein unberechenbares Risiko einzugehen!
Re: unqualifiziert
Zitat von cybercrash
Naja Cybercrash
Jetzt versteh ich nur Bahnhof vor lauter konservativen Risiko 8)
NEV ist risiko pur. Kursschwankung von +/-20 % innerhalb eines Monats sind für eine Beteiligung doch nicht konservativ.
Zitieren
